Effect of non‐steroidal anti‐inflammatory medications on the risk of amyotrophic lateral sclerosis

References

• McGeer P. L., McGeer E. G. Inflammation, autotoxicity and Alzheimer's disease. Neurobiol Aging 2001; 22: 799–809
   PubMed Web of Science ®Google Scholar
• Vila M., Jackson L. V., Guegan C. The role of glial cells in Parkinson's disease. Current Opinions in Neurology 2001; 14: 483–9
   PubMed Web of Science ®Google Scholar
• Hall E. D., Oostveen J. A., Gurney M. E. Relationship of microglial and astrocytic activation to disease onset and progression in a transgenic model of familial ALS. Glia 1998; 23: 249–56
   PubMed Web of Science ®Google Scholar
• Levine J. B., Kong J., Nadler M., Xu Z. Astrocytes interact intimately with degenerating motor neurons in mouse amyotrophic lateral sclerosis (ALS). Glia 1999; 28: 215–24
   PubMed Web of Science ®Google Scholar
• Schiffer D., Cordera S., Cavalla P., Migheli A. Reactive astrogliosis of the spinal cord in amyotrophic lateral sclerosis. J Neurol Sci 1996; 139((Suppl))27–33
   PubMed Web of Science ®Google Scholar
• Seibert K., Masferrer J., Zhang Y., Gregory S., Olson G., Hauser S., et al. Mediation of inflammation by cyclooxygenase‐2. Agents Actions 1995; 46((Suppl))41–50
   PubMedGoogle Scholar
• O'Banion M. K. Cyclooxygenase‐2: molecular biology, pharmacology, and neurobiology. Crit Rev Neurobiol 1999; 13: 45–82
   PubMed Web of Science ®Google Scholar
• Zandi P. P., Anthony J. C., Hayden K. M., Mehta K., Mayer L., Breitner J. C. Reduced incidence of AD with NSAID but not H2 receptor antagonists: the Cache County Study. Neurology 2002; 59: 880–6
   PubMed Web of Science ®Google Scholar
• Breitner J. C., Welsh K. A., Helms M. J., Gaskell P. C., Gau B. A., Roses A. D., et al. Delayed onset of Alzheimer's disease with non‐steroidal anti‐inflammatory and histamine H2 blocking drugs. Neurobiol Aging 1995; 16: 523–30
   PubMed Web of Science ®Google Scholar
• in t'Veld B. A., Ruitenberg A., Hofman A., Launer L. J., van Duijn C. M., Stijnen T., et al. Non‐steroidal anti‐inflammatory drugs and the risk of Alzheimer's disease. N Engl J Med 2001; 345: 1515–21
   PubMed Web of Science ®Google Scholar
• McGeer P. L., Schulzer M., McGeer E. G. Arthritis and anti‐inflammatory agents as possible protective factors for Alzheimer's disease: a review of 17 epidemiologic studies. Neurology 1996; 47: 425–32
   PubMed Web of Science ®Google Scholar
• Chen H., Zhang S. M., Hernan M. A., Schwarzschild M. A., Willett W. C., Colditz G. A., et al. Non‐steroidal anti‐inflammatory drugs and the risk of Parkinson's disease. Arch Neurol 2003; 60: 1059–64
   PubMed Web of Science ®Google Scholar
• Hernan M. A., Logroscino G., Garcia Rodriguez L. A. Non‐steroidal anti‐inflammatory drugs and the incidence of Parkinson's disease. Neurology 2006; 66: 1097–9
   PubMed Web of Science ®Google Scholar
• Krieger N. 1990, Resources of the Kaiser Permanente Medical Care Program in Northern California, Oakland, Division of Research, Kaiser Foundation Research Institute
   Google Scholar
• Krieger N. Overcoming the absence of socioeconomic data in medical records: validation and application of a census‐based methodology. Am J Pub Health 1992; 82: 703–10
   PubMed Web of Science ®Google Scholar
• Tandan R. Disorders of the upper and lower motor neuron. Neurology in Clinical Practice, W Bradley, R Daroff, G Fenichel, C Marsden. Butterworth‐Heinemann, Boston 1991; 1708–17
   Google Scholar
• Brooks B. R., Miller R. G., Swash M., Munsat T. L., World Federation of Neurology Research Group on Motor Neuron Diseases. El Escorial revisited: revised criteria for the diagnosis of amyotrophic lateral sclerosis. Amyotroph Lateral Scler Other Motor Neuron Disord 2000; 1: 293–9
   PubMed Web of Science ®Google Scholar
• Hosmer D. W Jr., Lemeshow S. Applied Logistic Regression. John Wiley & Sons, New York 1989
   Google Scholar
• Sansbury L. B., Millikan R. C., Schroeder J. C., Moorman P. G., North K. E., Sandler R. S. Use of non‐steroidal anti‐inflammatory drugs and risk of colon cancer in a population‐base, case‐control study of African Americans and Whites. Am J Epidemiol 2005; 162: 548–58
   PubMedGoogle Scholar
• Ridker P. M., Cook N. R., Lee I. M., Gordon D., Gaziano J. M., Manson J. E., et al. A randomized trial of low‐dose aspirin in the primary prevention of cardiovascular disease in women. N Engl J Med 2005; 352: 1293–1304
   PubMed Web of Science ®Google Scholar
• SAS Institute, Inc. [computer program] Version 8. SAS Institute Inc., Cary, NC 1999–2001
   Google Scholar
• Anderson G. D. Sex and racial differences in pharmacological response: where is the evidence? Pharmacogenetics, pharmacokinetics, and pharmacodynamics. J Womens Health. (Larchmt) 2005; 14: 19–29
   PubMed Web of Science ®Google Scholar
• Meibohm B., Beierle I., Derendorf H. How important are gender differences in pharmacokinetics?. Clin Pharmacokinet 2002; 41: 329–42
   PubMed Web of Science ®Google Scholar
• Sorenson E. J., Stalker A. P., Kurland L. T., Windebank A. J. Amyotrophic lateral sclerosis in Olmsted County, Minnesota, 1925 to 1998. Neurology 2002; 59: 280–2
   PubMed Web of Science ®Google Scholar
• Signorello L. B., McLaughlin J. K., Lipworth L., Friis S., Sorensen H. T., Blot W. J. Confounding by indication in epidemiologic studies of commonly used analgesics. Am J Ther 2002; 9: 199–205
   PubMedGoogle Scholar
• Cudkowicz M. E., Shefner J. M., Schoenfeld D. A., Zhang H., Andreasson K. I., Rothstein J. D., et al. Trial of celecoxib in amyotrophic lateral sclerosis. Ann Neurol 2006; 60: 22–31
   PubMed Web of Science ®Google Scholar